High grade gliomas (HGG), including glioblastoma, are the most common malignant primary brain tumour types. Advances in treating HGG are hampered by the lack of good non-invasive biomarkers for early response or relapse. Magnetic Resonance techniques are unique and indispensable for non-invasive metabolic imaging, and could make a difference in oncology and neurology. Despite its huge proven potential, MRS(I) is not yet a routine clinical tool operated solely by clinicians, as this requires reliable automation of complex procedures, strengthening standardization and quality control.